1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Slovakia Pharmaceuticals and Healthcare Report Q3 2016

Slovakia Pharmaceuticals and Healthcare Report Q3 2016

  • June 2016
  • -
  • Business Monitor International
  • -
  • 91 pages

Includes 3 FREE quarterly updates

BMI View: Slovakia will remain a modest investment opportunity for multinational drugmakers. Whileexpenditure for both healthcare and pharmaceuticals is high, greater funding efficiency is needed. Recentyears have been turbulent for the healthcare sector, with a lack of progress on new legislation apparent.The appointment of a new minister of health is hoped to improve the situation, but the outlook remainsunclear.

Headline Expenditure Projections

- Pharmaceuticals: EUR1.91bn (USD2.10bn) in 2015 to EUR1.97bn (USD2.12bn) in 2016; +2.8% inlocal currency terms and +0.6% in US dollar terms. Forecast unchanged from last quarter.

- Healthcare: EUR6.15bn (USD6.76bn) in 2015 to EUR6.38bn (USD6.86bn) in 2016; +3.7% in localcurrency terms and +1.5% in US dollar terms. Forecast revised slightly downwards from last quarter.

Table Of Contents

Slovakia Pharmaceuticals and Healthcare Report Q3 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Slovakia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Slovakia 2012-2020) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Slovakia 2012-2020) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Slovakia 2012-2020) 22
Generic Drug Market Forecast 23
Table: Members Of GENAS, 2015 25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Slovakia 2012-2020) 26
OTC Medicine Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Slovakia 2012-2020) 29
Pharmaceutical Trade Forecast 30
Table: Pharmaceutical Trade Data And Forecasts (Slovakia 2014-2020) 32
Table: Pharmaceutical Trade Data And Forecasts local currency (Slovakia 2014-2020) 32
Industry Risk/Reward Index 33
Central And Eastern Europe Risk/Reward Index - Q3 2016 33
Slovakia Risk/Reward Index 39
Rewards 39
Risks 39
Regulatory Review 41
Regulatory Regime 41
Intellectual Property Issues 44
Pricing Regime 45
Table: Indexed Price Build-Up For Prescription And Non-Prescription Medicines In Slovakia 46
Reimbursement Regime 46
Market Overview 52
Healthcare Sector 52
Table: Healthcare Resources (Slovakia 2010-2015) 55
Table: Healthcare Personnel (Slovakia 2010-2015) 55
Table: Healthcare Activity (Slovakia 2010-2015) 56
Research And Development 60
Table: Members Of BITCET, 2011 61
Table: Members Of SLOVBIOTECH, 2010 62
Clinical Trials 62
Epidemiology 63
Table: Main Causes Of Mortality And Morbidity In Slovakia 64
Competitive Landscape 66
Research-Based Industry 66
Table: Members Of SAFS, 2012 66
Table: Multinational Market Activity 67
Generic Drugmakers 68
Table: Registered Pharmaceutical Manufacturers 68
Pharmaceutical Distribution 69
Table: ADL Members, 2012 (Manufacturers, unless otherwise indicated) 70
Pharmaceutical Retail Sector 70
Company Profile 73
Biotika 73
HBM Pharma 75
Imuna Pharma 78
Demographic Forecast 80
Table: Population Headline Indicators (Slovakia 1990-2025) 81
Table: Key Population Ratios (Slovakia 1990-2025) 81
Table: Urban/Rural Population and Life Expectancy (Slovakia 1990-2025) 82
Table: Population By Age Group (Slovakia 1990-2025) 82
Table: Population By Age Group % (Slovakia 1990-2025) 83
Glossary 85
Methodology 87
Pharmaceutical Expenditure Forecast Model 87
Healthcare Expenditure Forecast Model 87
Notes On Methodology 88
Risk/Reward Index Methodology 89
Index Overview 90
Table: Pharmaceutical Risk/Reward Index Indicators 90
Indicator Weightings 91

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
OpportunityAnalyzer: Huntington’s Disease - Opportunity Analysis and Forecast to 2024

OpportunityAnalyzer: Huntington’s Disease - Opportunity Analysis and Forecast to 2024

  • $ 9 495
  • Industry report
  • May 2016
  • by Global Data

OpportunityAnalyzer: Huntington’s Disease - Opportunity Analysis and Forecast to 2024 Summary Huntington’s Disease (HD) is a rare, autosomal-dominant, neurodegenerative disorder, characterized by impaired ...

Asthma Pricing, Reimbursement, and Access

Asthma Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • May 2016
  • by Datamonitor Healthcare

Growth in the asthma market will be fueled by the introduction of new and expensive biologics, but companies will have to navigate access restrictions imposed by payers concerned about budget impact. This ...

Multiple Myeloma Pricing, Reimbursement, and Access

Multiple Myeloma Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • May 2016
  • by Datamonitor Healthcare

Growth in the multiple myeloma market will be spurred by the approval of novel drugs and the increasing role of combination therapy, but risk-sharing agreements will be key to entry into increasingly restrictive ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.